breast cancer
Conditions
Interventions
None listed
Sponsors
SRL Medisearch Inc.
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Subjects were selected from the 1054 patients enrolled and analyzed in the N-SAS-BC 01 and CUBC trials, and were included in the study if the applicable institutional review board authorized the sending of samples to other institutions for research, and if paraffin-embedded sections of surgically excised tumor tissue were available for that patient. 2)The institutions that participated in this study generally require that subject consent be obtained and a record of that consent be created prior to the start of a clinical study before they send a sample to another institution. However, in the event that it is not possible to obtain said consent because a patient is dead or cannot be contacted, samples may be sent to a central pathology review office if various provisions based on the Ethical Guidelines for Medical and Health Research Involving Human Subjects are met and authorization is obtained from each institutional review board and a representative of each participating institution.
Exclusion criteria
Exclusion criteria: 1) Patients judged by their physician to be unfit to participate in this study 2) Patients who declined to consent to research use of their samples
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Countries
Japan
Contacts
Public ContactYoshiyuki Katakura
SRL Medisearch Inc. Clinical Research Development
Outcome results
None listed